SecBot SecBot
SECBOTREPLAY Home › Report › TVTX

TVTX · Travere Therapeutics announced the planned retirement of CAO Sandra…

Travere Therapeutics, Inc. · 8-K filed Jul 9, 2026 at 17:10 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jul 9, 2026 at 17:10 ET

Travere Therapeutics announced the planned retirement of CAO Sandra Calvin after the filing of the 2026 10-K (expected February 2027), with VP Controller John Torell set to succeed her. The transition is orderly with an internal replacement already named, making this a routine personnel event with no material financial impact.

  • CAO Sandra Calvin intends to retire following the filing of the 2026 annual report (expected February 2027).
  • John Torell, CFA, CPA, currently VP Controller, is expected to succeed her as CAO and PAO.
  • Torell joined Travere in 2021 and has overseen accounting operations, financial reporting, SEC reporting, and internal controls.
  • The Board is expected to appoint Torell in advance of the Retirement Date to ensure an orderly transition.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access